Home › Spinal Muscular Atrophy › Georgia › Atlanta
Spinal Muscular Atrophy clinical trials in Atlanta, GA
3 studies for Spinal Muscular Atrophy are looking for participants at sites in and around Atlanta (within about 30 miles). Open a study to see who can join and how to contact the study team.
A Study to Evaluate How Apitegromab Works in Subjects Who Are Less Than 2 Years Old and Have Spinal Muscular Atrophy
RecruitingPhase 2
- Children's Healthcare of Atlanta, Atlanta
A Study Evaluating the Effectiveness and Safety of Risdiplam Administered in Pediatric Patients With Spinal Muscular Atrophy Who Experienced a Plateau or Decline in Function After Gene Therapy
RecruitingPhase 4
- Children's Healthcare of Atlanta Center for Advanced Pediatrics, Atlanta
A Study Evaluating the Effectiveness and Safety of Risdiplam Administered as an Early Intervention in Pediatric Participants With Spinal Muscular Atrophy After Gene Therapy
RecruitingPhase 4
- Children's Healthcare of Atlanta Center for Advanced Pediatrics, Atlanta
About Spinal Muscular Atrophy
Spinal muscular atrophy (SMA) attacks nerve cells in the spinal cord, weakening voluntary muscles. Read about the genetics, types, and what may help.
More about Spinal Muscular Atrophy on MedlinePlus
Spinal Muscular Atrophy trials in other cities
- New York City, NY9 studies
- Mountain View, CA8 studies
- Philadelphia, PA7 studies
- Norfolk, VA6 studies
- Chicago, IL6 studies
- Grand Rapids, MI6 studies
- Houston, TX5 studies
- Boston, MA5 studies
- Aurora, CO4 studies
- Little Rock, AR4 studies
- Memphis, TN4 studies
- Phoenix, AZ4 studies
Other studies in Atlanta
- Cancer (all types)50 studies
- Non-Small Cell Lung Cancer46 studies
- Breast Cancer41 studies
- Multiple Myeloma41 studies
- Prostate Cancer32 studies
- Colorectal Cancer29 studies
- Lung Cancer29 studies
- Ovarian Cancer28 studies
- Acute Myeloid Leukemia28 studies
- Obesity27 studies
- Metastatic Cancer27 studies
- Heart Failure25 studies
From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.